Core Insights - Cidara Therapeutics, Inc. is participating in two upcoming investor conferences in November 2025, including the Guggenheim 2 Annual Healthcare Innovation Conference and the Jefferies London Healthcare Conference [1][2] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) therapeutics, with a focus on targeted small molecules or peptides linked to a human antibody fragment [3] - The lead DFC candidate, CD388, is designed for long-acting antiviral treatment aimed at universal prevention of seasonal and pandemic influenza with a single dose by inhibiting viral proliferation [3] - CD388 received Fast Track Designation from the FDA in June 2023 and has shown positive top-line results from its Phase 2b NAVIGATE trial in June 2025, with a Phase 3 ANCHOR trial initiated in September 2025 [3]